Anemia and the use of antihypertensive medications in hemodialysis patients: multicenter retrospective observational study

  • N. Stepanova State Institute «Institute of Nephrology of the National Academy of Medical Sciences of Ukraine» https://orcid.org/0000-0002-1070-3602
  • V. Novakivskyy LLC "Fresenius Medical Care Ukraine" Medical Centre
  • L. Snisar State Institute «Institute of Nephrology of the National Academy of Medical Sciences of Ukraine»
  • M. Kutsenko State Institute «Institute of Nephrology of the National Academy of Medical Sciences of Ukraine»
Keywords: anemia, antihypertensive medications, hemodialysis

Abstract

Abstract. We hypothesized that the use of antihypertensive medications in patients treated by hemodialysis (HD) may interfere with the activity of erythropoietin and leads to an increase in the dose of erythropoiesis stimulating agents (ESAs).

The aim of our study was to analyze the impact of antihypertensive medications on the effectiveness of anemia treatment.

Methods. We conducted a multicenter retrospective observational study. The archival medical data from 379 patients treated by HD or hemodiafiltration (HDF) were used. The medical records of 142 patients were excluded from the study. The study group consisted of 237 patients: 108 (45.6%) women and 129 (54.4%) men, with an average age of 54 [41-62.5] years.

Results. The analysis of the mean hemoglobin (Hb) stratified by the administration of antihypertensive medications in the dynamics of dialysis treatment demonstrated a significant impact of angiotensin-converting enzyme (ACE) inhibitors (F = 3.97; p = 0.048) and amlodipine (F = 6.9; p = 0.01) on the effectiveness of anemia correction. The significant effect of amlodipine on the need to increase the dosage of iron-containing medications (OR = 3.9; 95% CI (1.27-12.06), p = 0.002; RR = 1.9 95% CI (1.27-2.9) and continuous erythropoietin receptor activator (CERA) (OR = 5.2, 95% CI (1.2-24.4), p = 0.03; RR = 1.3 95% CI (1, 08-1.6), p = 0.006) weas showed by logistic regression analysis. The increased risk of failure to achieve of the target Hb level in HD patients received amlodipine was confirmed by Cox regression model (HR = 2.7 (95% CI 1.5-4.7)).

Conclusions: The results of our study demonstrated a significant increase in the frequency of appointment and amount of anti-anemia therapy in HD patients when amlodipine is co-administered. Follow-up studies to determine the effect of amlodipine mechanism for anemia will avoid unreasonable prescriptions for the treatment of НD patients.

Conflict of interest statement: the authors declared no competing interests.

Downloads

Download data is not yet available.

References

Kalantar-Zadeh K. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology. Am J Nephrol. 2017;45:235-247. doi: 10.1159/000455387.

KDIGO: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. Suppl. 2012;2: 279–335. doi:10.1038/kisup.2012.44.

Ogawa T, Nitta K. Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients. Contrib Nephrol. 2015;185:76-86. doi: 10.1159/000380972.

Locatelli F, Aljama P, Bárány P. et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19 Suppl 2:32-36.

Kolesnyk MO, hol. redaktor. Natsionalnyi reiestr khvorykh na khronichnu khvorobu nyrok ta patsiientiv z  hostrym poshkodzhenniam nyrok: 2017 rik / uklad. NI Kozliuk, SS Nikolaienko, OО Razvazhaieva; Derzhavna ustanova «Instytut nefrolohii NAMN Ukrainy». Kyiv, 2018.183 s. [In Ukrainian].

Sica DA, Mannino R. Antihypertensive Medications and Anemia. The Journal of Clinical Hypertension. 2007;9:723-727. doi:10.1111/j.1524-6175.2007.06296.x

Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton). 2007;12(4):321-30. doi: 10.1111/j.1440-1797.2007.00810.x.

Cheungpasitporn W, Thongprayoon C, Chiasakul T, Korpaisarn S, Erickson SB. Renin-angiotensin system inhibitors linked to anemia: a systematic review and meta-analysis. QJM. 2015;108(11):879-84. doi: 10.1093/qjmed/hcv049.

Inoue A1, Babazono T, Iwamoto Y. Effects of the Renin-Angiotensin system blockade on hemoglobin levels in type 2 diabetic patients with chronic kidney disease. Am J Hypertens. 2008;21(3):317-22. doi: 10.1038/ajh.2007.53.

Hirakata H, Onoyama K, Iseki K, Kumagai H, Fujimi S, Omae T. Worsening of anemia induced by long-term use of captopril in hemodialysis patients. Am J Nephrol. 1984;4(6):355-60. doi.: 10.1159/000166851

Ishani A, Weinhandl E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S, et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2005;45(3):391–9. doi.:10.1016/j.jacc.2004.10.038

Azizi M, Rousseau A, Ezan E, et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest. 1996;97(3):839-44. doi: 10.1172/JCI118484

Kiss Z, Ambrus C, Kulcsár I, Szegedi J, Kiss I. Effect of angiotensin-converting enzyme gene insertion/deletion polymorphism and angiotensin-converting enzyme inhibition on erythropoiesis in patients on haemodialysis. J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):1021-7. doi: 10.1177/1470320314535276.

Saudan P, Halabi G, Perneger T, Wasserfallen JB, Wauters JP, Martin PY.  ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance. J Nephrol. 2006 Jan-Feb;19(1):91-6.

Piccoli A, Pastori G, Pierobon E, Torraca S, Andreucci M, Sabbatini M, et al. Anti-renin-angiotensin-system drugs and development of anemia in chronic kidney disease. J Nephrol. 2005;18(5):585–91.

Qureshi IZ, Abid K, Ambreen F, Qureshi AL. Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure. Saudi Med J. 2007 Feb;28(2):193-6.

Wühl E, Mehls O, Schaefer F. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int. 2004 Aug;66(2):768-76. doi: 10.1111/j.1523-1755.2004.00802.x

Cikrikcioglu MA, Karatoprak C, Cakirca M, Kiskac M, Zorlu M, Cetin G, et al. Association of calcium channel blocker use with lower hemoglobin levels in chronic kidney disease. Eur Rev Med Pharmacol Sci 2013; 17 (18): 2530-2537.

Sarafidis PA, Persu A, Agarwal R, Burnier M, de Leeuw P, Ferro C, et al. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). J Hypertens. 2017 Apr;35(4):657-676. doi: 10.1097/HJH.0000000000001283.

Icardi A, Paoletti E, De Nicola L, Mazzaferro S, Russo R, Cozzolino M. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. Nephrol Dial Transplant. 2013 Jul;28(7):1672-9. doi: 10.1093/ndt/gft021.

Likuvannia khvorykh na z khronichnu khvorobu nyrok V HD stadii. Adaptovana klinichna nastanova, zasnovana na dokazakh ta unifikovani klinichni protokoly. – K. : «Polihraf plius», 2016. – 228 s. [In Ukrainian].

Schneider A, Schneider MP, Scharnagl H, Jardine AG, Wanner C, Drechsler C. Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes. BMC Nephrol. 2013;14:67. doi:10.1186/1471-2369-14-67

Samavat S , Nafar M, Khoshdel A, Alipour- Abedi B. Factors Contributing to Erythropoietin Hyporesponsiveness Among Hemodialysis PSamavat Satients: A Cross-Sectional Multicenter Study, Nephro-Urol Mon. 2017 ; 9(3):e45003. doi: 10.5812/numonthly.45003.

Fernandes JL, Sampaio EF, Fertrin K, Coelho OR, Loggetto S, Piga A, et al. Amlodipine reduces cardiac iron overload in patients with thalassemia major: a pilot trial. Am J Med. 2013 Sep;126(9):834-7. doi: 10.1016/j.amjmed.2013.05.002. doi: 10.1111/ejh.12977

Bogdanova A, Makhro A, Wang J, Lipp P, Kaestner L. Calcium in red blood cells-a perilous balance. Int J Mol Sci. 2013;14(5):9848-72. Published 2013 May 8. doi:10.3390/ijms14059848.

Joseph Y. Cheung, Xue-Qian Zhang, Krister Bokvist, Douglas L. Tillotson, Barbara A. Millerю Modulation of Calcium Channels in Human Erythroblasts by Erythropoietin. Blood Jan 1997, 89 (1) 92-100.

Zhang Y, Zhao X, Chang Y, Zhang Y, Chu X, Zhang X, et al. Calcium channel blockers ameliorate iron overload-associated hepatic fibrosis by altering iron transport and stellate cell apoptosis . Toxicol Appl Pharmacol. 2016 Jun 15;301:50-60. doi: 10.1016/j.taap.2016.04.008.


Abstract views: 152
PDF Downloads: 59
Published
2019-02-04
How to Cite
Stepanova, N., Novakivskyy, V., Snisar, L., & Kutsenko, M. (2019). Anemia and the use of antihypertensive medications in hemodialysis patients: multicenter retrospective observational study. Ukrainian Journal of Nephrology and Dialysis, (1(61), 29-38. https://doi.org/10.31450/ukrjnd.1(61).2019.04